| |
Integrated Safety Analysis of 24-Week Data From Three Phase 2 and One Phase 3 Clinical Trial of Bulevirtide Monotherapy Given at 2- or 10-mg Dose Level for Treatment of Chronic Hepatitis Delta
|
| |
| |
EASL 2022 June 22-26 London
Pietro Lampertico,1,2 Soo Aleman,3 Tarik Asselah,4 Marc Bourliere,5 Adrian Streinu-Cercel,6 Pavel Bogomolov,7 Viacheslav Morozov,8 Tatyana Stepanova,9 Stefan Lazar,10 Vithika Suri,11 Dmitry Manuilov,11 Lei Ye,11 John F. Flaherty,11 Anu Osinusi,11 Maurizia Brunetto,12 Heiner Wedemeyer13
1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy; 2"A.M. e A. Migliavacca" Center for the Study of Liver Disease, Università degli Studi di Milano, Italy; 3Karolinska Universitetssjukhuset/Karolinska Institutet, Stockholm, Sweden; 4Hôpital Beaujon, Université de Paris, Clichy, France; 5Hôpital Saint Joseph Marseille, France; 6Institutul Național de Boli Infecțioase "Prof. Dr. Matei Balș," Bucureşti, Romania;
7Moscow Regional Research Clinical Institute Named After M. F. Vladimirsky, Moscow, Russian Federation; 8Hepatolog, Samara, Russian Federation; 9Clinic of Modern Medicine, Moscow, Russian Federation; 10Spitalului Clinic de Boli Infecţioase şi Tropicale "Dr. Victor Babeş," Bucureşti; 11Gilead Sciences, Inc., Foster City, California, USA; 12Hepatology Unit, University Hospital of Pisa, Italy; 13Medizinische Hochschule Hannover, Germany
|
|
| |
| |
|
|
|
